Sign In
Buy LMLLF
$0.0037
+0 (+0%)
At Close: Jun 22, 2026
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
08:00am, Monday, 19'th Aug 2024
Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, develo
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
08:00am, Wednesday, 15'th May 2024
Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, developme
PharmaDrug Announces Director Appointment and Resignation
04:40pm, Thursday, 02'nd May 2024
Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, developmen
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
08:50am, Wednesday, 01'st May 2024
Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, developmen
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
08:00am, Tuesday, 27'th Feb 2024
Toronto, Ontario--(Newsfile Corp. - February 27, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, deve
PharmaDrug's Sairiyo Therapeutics pursuing in-human study of PD-001 in Australia following manufacturing milestone
09:33am, Wednesday, 14'th Feb 2024
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that its majority-owned subsidiary Sairiyo Therapeutics has successfully demonstrated the ability to manufacture clinical GMP manufacturing batches of
PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
08:25am, Wednesday, 14'th Feb 2024
Company to pursue regulatory filing for Phase I/II clinical study Toronto, Ontario--(Newsfile Corp. - February 14, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company")
PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers
08:44am, Monday, 12'th Feb 2024
Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), today announced that it has entered into (i) a marketing and dis
PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
04:30pm, Thursday, 08'th Feb 2024
Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce the closing of its previously announced no
PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
08:00am, Thursday, 01'st Feb 2024
Toronto, Ontario--(Newsfile Corp. - February 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce a proposed non-brokered private placement
PharmaDrug to continue Securedose Synthetics' R&D activities following acquisition
08:58am, Wednesday, 13'th Dec 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) said it plans to continue to carry out Securedose Synthetics' strategy of developing synthetic formulations of existing drugs for potential commercialization and
PharmaDrug Inc. Announces Grant of Stock Options
05:23pm, Wednesday, 08'th Nov 2023
Toronto, Ontario--(Newsfile Corp. - November 8, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), announces that it has granted a total of 6,250,000 stock options
PharmaDrug closes Securedose Synthetics acquisition
08:31am, Tuesday, 07'th Nov 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) said it has completed its previously announced acquisition of Securedose Synthetics Inc by way of a three-cornered amalgamation between Pharmadrug, SecureDose
PharmaDrug Inc. Closes Acqusition of Securedose Synthetics
07:30am, Tuesday, 07'th Nov 2023
Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) ("PharmaDrug" or the "Company"), is pleased to announce that it has closed the previously announce
PharmaDrug to acquire Securedose Synthetics in all-stock deal
09:07am, Friday, 27'th Oct 2023
PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced that it will acquire all of the issued and outstanding shares of Securedose Synthetics Inc, a privately-held pharmaceutical Research and Development c
